Hematopoietic capacity and exceptional survival: the Leiden Longevity Study

Area of Science:

• Gerontology and Hematology
• Population Health Studies
• Genetics of Aging

Background:

• Familial longevity is associated with better survival rates in older adults.
• The role of hematopoietic capacity in exceptional longevity remains unclear.
• Understanding factors contributing to long lifespan is crucial for public health.

Purpose of the Study:

• To investigate whether sustained hematopoietic capacity contributes to familial longevity.
• To examine the association between blood cell counts and survival in nonagenarians with and without familial longevity.

Main Methods:

• Prospective follow-up of two independent population-based cohorts: the Leiden Longevity Study and the Leiden 85-plus Study.
• Inclusion of 1,001 nonagenarians with familial longevity and 260 age-matched controls without familial longevity.
• Measurement of hemoglobin, leukocytes, and thrombocytes, with statistical analysis using standardized mortality ratios and regression models.

Main Results:

• Nonagenarians with familial longevity exhibited 28% lower mortality compared to the general population.
• No significant differences in hemoglobin, leukocyte, or thrombocyte counts were observed between groups with and without familial longevity.
• Anemia was associated with a significantly increased mortality risk (hazard ratio=1.71) in nonagenarians with familial longevity.

Conclusions:

• Hematopoietic capacity does not explain the enhanced survival in nonagenarians with familial longevity.
• Anemia appears to be a significant risk factor for mortality among individuals with familial longevity.
• Further research into anemia's impact on extreme longevity is warranted.